Target: ₹3,400
CMP: ₹3,053.50
Dr Lal Pathlabs’ (DLPL) Q2-FY25 margins expanded by 110bps y-o-y on the back of improving contribution from Swasthfit and better margin performance at Suburban (about 600 bps q-o-q). Sample volume growth (+8.6 per cent y-o-y), however, remained soft owing to lower incidence of monsoon-related illnesses (except West region) and a higher base.
With the management’s target of adding 15-20 labs in FY25, signs of Suburban turning around, and predatory pricing receding, we anticipate 13 per cent revenue CAGR over FY24-27. Ramp up from hospital-backed chains remain a key risk for the well-diversified revenue base of DLPL, in our view.
A strong balance sheet, industry leading margins, and improving return ratios provide comfort on valuations. We retain Buy with a revised Sep-25E target price of ₹3,400 (based on DCF), implying FY26E PER of 55x (in line with LTA).
The company has announced an interim dividend of ₹6/share for the quarter. Capex for the quarter was ₹10.60 crore and net cash on books stood at nearly ₹1,100 crore.
Key risks: Increased competition in the organised market from growing hospital chains, predatory pricing from any market participants, and adverse regulatory ruling around pricing cap for healthcare services.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.